Clinical Trial Update: Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing Nab-TPC versus GP, both with camrelizumab, in recurrent/metastatic nasopharyngeal carcinoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Camrelizumab (camrelizumab)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Cancinoma (NPC) | Phase 3 | Status: RECRUITING